Castle Biosciences (Castle Biosciences) Debt-to-EBITDA : 5.60 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Castle Biosciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Castle Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.1 Mil. Castle Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $14.2 Mil. Castle Biosciences's annualized EBITDA for the quarter that ended in Dec. 2023 was $2.7 Mil. Castle Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 5.60.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Castle Biosciences's Debt-to-EBITDA or its related term are showing as below:

CSTL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.51 Med: -0.29 Max: 2.44
Current: -0.34

During the past 7 years, the highest Debt-to-EBITDA Ratio of Castle Biosciences was 2.44. The lowest was -6.51. And the median was -0.29.

CSTL's Debt-to-EBITDA is ranked worse than
100% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.8 vs CSTL: -0.34

Castle Biosciences Debt-to-EBITDA Historical Data

The historical data trend for Castle Biosciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Castle Biosciences Debt-to-EBITDA Chart

Castle Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

2.44

-0.22

-0.23

-0.34

Castle Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.19	-0.12	-0.23	-0.98	5.60

Competitive Comparison of Castle Biosciences's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Castle Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Castle Biosciences's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Castle Biosciences's Debt-to-EBITDA falls into.

Castle Biosciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Castle Biosciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.137	+	14.198)	/	-45.024
	=	-0.34

Castle Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.137	+	14.198)	/	2.74
	=	5.60

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Castle Biosciences (NAS:CSTL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Castle Biosciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Castle Biosciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Castle Biosciences (Castle Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Castle Biosciences Inc (NAS:CSTL) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 S. Friendswood Drive, Suite 401, Friendswood, TX, USA, 77546

Website

https://www.castlebiosciences.com

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

Executives

Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Derek J Maetzold	director, 10 percent owner, officer: Pres. & Chief Exec. Officer	820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Ellen Goldberg	director	C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Tiffany Olson	director	C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Kristen M Oelschlager	officer: Chief Operating Officer	C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Bernhard E. Spiess	officer: Chief Operating Officer	C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Kim Caple	director	C/O BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Frank Stokes	officer: Chief Financial Officer	C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Tobin W Juvenal	officer: Chief Commercial Officer	C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
David S Kabakoff	director, 10 percent owner	C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Cook Joseph C. Iii	director, 10 percent owner	C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, STE. 201, FRIENDSWOOD TX 77546
Mara G. Aspinall	director	7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Bonnie H Anderson	director	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mgc Venture Partners 2013 Gp, Llc	10 percent owner	C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203
Mgc Venture Partners 2013, L.p.	10 percent owner	C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203